<SEC-DOCUMENT>0001209191-17-026989.txt : 20170414
<SEC-HEADER>0001209191-17-026989.hdr.sgml : 20170414
<ACCEPTANCE-DATETIME>20170414173702
ACCESSION NUMBER:		0001209191-17-026989
CONFORMED SUBMISSION TYPE:	3/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170412
FILED AS OF DATE:		20170414
DATE AS OF CHANGE:		20170414

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RXi Pharmaceuticals Corp
		CENTRAL INDEX KEY:			0001533040
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		257 SIMARANO DRIVE
		STREET 2:		SUITE 101
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752
		BUSINESS PHONE:		(508) 767-3861

	MAIL ADDRESS:	
		STREET 1:		257 SIMARANO DRIVE
		STREET 2:		SUITE 101
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Eliseev Alexey
		CENTRAL INDEX KEY:			0001694380

	FILING VALUES:
		FORM TYPE:		3/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36304
		FILM NUMBER:		17763332

	MAIL ADDRESS:	
		STREET 1:		257 SIMARANO DRIVE, SUITE 101
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752
</SEC-HEADER>
<DOCUMENT>
<TYPE>3/A
<SEQUENCE>1
<FILENAME>doc3a.xml
<DESCRIPTION>FORM 3/A SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3/A</documentType>

    <periodOfReport>2017-04-12</periodOfReport>

    <dateOfOriginalSubmission>2017-01-17</dateOfOriginalSubmission>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001533040</issuerCik>
        <issuerName>RXi Pharmaceuticals Corp</issuerName>
        <issuerTradingSymbol>RXII</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001694380</rptOwnerCik>
            <rptOwnerName>Eliseev Alexey</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O 257 SIMARANO DRIVE, SUITE 101</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>MARLBOROUGH</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>01752</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Business Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series C Convertible Preferred Stock, $0.0001 par value</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>332499</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Series C Convertible Preferred Stock will automatically convert into common stock upon approval by the Company's stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635 without payment of consideration. The Series C Convertible Preferred Stock have no expiration.</footnote>
        <footnote id="F2">Represents securities issued to the reporting person in connection with the acquisition of MirImmune Inc. on January 6, 2017. Up to 3% of the shares were subject to a holdback for post-closing adjustments in certain circumstances. This amount reflects the securities issued to the reporting person as a result of those post-closing adjustments and differs from the number of shares initially reported as a result of more shares being issuable in the acquisition pursuant to the Stock Purchase Agreement than initially estimated.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>Caitlin Kontulis, attorney-in-fact</signatureName>
        <signatureDate>2017-04-14</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
